EURO-TEAM
Towards Early diagnosis and biomarker validation in Arthritis Management
| Coordinatore | THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.team-arthritis.eu |
| Totale costo | 7˙609˙029 € |
| EC contributo | 5˙777˙374 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2016-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
UK (BIRMINGHAM) | coordinator | 1˙245˙220.00 |
| 2 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 549˙999.00 |
| 3 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 518˙800.00 |
| 4 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 417˙600.00 |
| 5 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 358˙040.00 |
| 6 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 357˙800.00 |
| 7 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 351˙970.00 |
| 8 |
ORGENTEC DIAGNOSTIKA GMBH
Organization address
address: CARL ZEISS STRASSE 49 contact info |
DE (MAINZ) | participant | 347˙850.00 |
| 9 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 252˙800.00 |
| 10 |
ARTHROGEN BV
Organization address
address: Meibergdreef 45 contact info |
NL (AMSTERDAM ZUIDOOST) | participant | 236˙295.00 |
| 11 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 218˙000.00 |
| 12 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 218˙000.00 |
| 13 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: Valhallavaegen 79 contact info |
SE (STOCKHOLM) | participant | 210˙200.00 |
| 14 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 178˙800.00 |
| 15 |
UNIVERSITATSKLINIKUM ERLANGEN
Organization address
address: Maximiliansplatz 2 contact info |
DE (ERLANGEN) | participant | 158˙000.00 |
| 16 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 158˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early phases of disease. The key objective of the TEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to rheumatoid arthritis. Our consortium will achieve this by developing a collaborative, integrated programme of work that links researchers with key SMEs involved in biomarker development to produce a “personalized predictive bioprofile” for patients destined to develop RA. The Euro-TEAM consortium will deliver a step change in the development of biomarkers and diagnostic kits that are timely, strategically important for European SMEs, and based on a disease (RA) in which concrete genetic and environmental risk factors have already been established. Firstly, it will directly compare biomarkers in the preclinical phases of disease with established markers in the clinical phases. Secondly, it will look beyond the synovium interrogating lymphoid, lung and periodontal tissue in a first-in-class approach to measuring systemic changes in the earliest phases of disease. Thirdly, it will place great emphasis on understanding why synovial inflammation resolves in some individuals and develop biomarkers of this “reverse” phase. Fourthly, it will explore a key cell type (stromal cells) that has been almost completely ignored in current biomarker studies. Finally, it will directly involve patients and other specialists, particularly from the fields of genetics, ethics and patient and public involvement in helping to visualize and communicate risk following a positive biomarker test.'